简介：

简介：

简介：

简介：磨擦促使焊接(FSW)并且静止肩膀磨擦促使焊接(SSFSW)为与2的厚度不一样的AA2024-T3和AA7050-T7651铝合金加入的靶子被执行?公里。当使旋转速度不变时，在二个过程之间的比较被改变焊接速度执行。通过在焊接和一个简单分析模型期间生产的力量和转矩的分析，生产的工具和热是更高效地分布式的，对在SSFSW，有更有效的结合的表演可能。这进程减少在二合金的接口的焊接区域和散开与FSW相比。最小的microhardness在进展方面发生了(作为)在在thermo机械地影响的地区(TMAZ)和在两个的stir地区(SZ)之间的接口处理，尽管减少在SSFSW是更渐渐的。这个接口也是所有标本为两个都焊接技术失败了的地方。张力的力量的增加与标准FSW相比在SSFSW被测量。而且，用数字图象关联在破裂地区建立材料的机械性能是可能的。

简介：Althoughthegreyforecastingmodelhasbeensuccessfullyadoptedinvariousfieldsanddemonstratedpromisingresults,theliteraturesshowitsperformancecouldbefurtherimproved,suchasfortheDGM(1,1)model,basedonaconcavesequence,themodelingerrorwillbelarger.Inthispaper,firstlythedefinitionofsequenceconvexityisgivenout,anditisprovedthattheoutputsequenceofDGM(1,1)modelisaconvexsequence.Next,theresidualchangelawofDGM(1,1)modelbasedontheconcavesequenceisdiscussed,andthenon-equidistanceDGM(1,1)modelisproposed.Finally,byintroducingthesymmetrytransformation,aconcavesequenceistransformedintoaconvexsequence,calledthesymmetricsequenceoftheconcavesequence,andthenconstructthenon-equidistanceDGM(1,1)modelbasedontheconvexsequence.Theexampleresultsshowthatthenovelmethodismoreaccuratethanthedirectmodelingforaconcavesequence.

简介：

简介：

简介：Objective:Survivalbenefitofadjuvantchemotherapy(AC)ofpatientswithintrapulmonarylymphnode(IPLN)metastasis(level12-14)needsinvestigation.WeevaluatedtheimpactofAConpatientswhosemetastaticnodeswerelimitedtointrapulmonarylevelsaftersystematicdissectionofN1nodes.Methods:First,155consectivecasesoflungcancerconfirmedaspathologicN1werecollectedandevaluated.PatientsreceivedsystematicdissectionofN2andN1nodes.ForpatientswithIPLNmetastasis,survivaloutcomeswerecomparedbetweenthosereceivingACandthosenotreceivingAC.Results:Inthisgroup,112cases(72.3%)hadIPLNmetastasisand55cases(35.5%)hadN1involvementlimitedtolevel13-14withoutfurtherdiseasespreadtohigherlevels.PatientswithIPLNinvolvementhadabetterprognosisthanthatofpatientswithhilar-interlobarinvolvement.FortheintrapulmonaryN1group(level12-14-positive,level10-11-negativeorunknown,n=112),nosurvivalbenefitwasfoundbetweentheACgroupandnonACgroup[5-yearoverallsurvival(OS):54.6±1.6vs.50.4±2.4months,P=0.177].However,76of112casesforwhomharvestingoflevel-10andlevel-11nodeswasdonedidnotshowcancerinvolvementinpathologyreports(level12-14-positive,level10-11bothnegative),oncologicoutcomewasbetterforpatientsreceivingACthanthosenotreceivingACinthissubgroup(5-yearOS:57.3±1.5vs.47.1±3.2months,P=0.002).Conclusions:OncologicoutcomemaybeimprovedbyACforpatientswithinvolvementofN1nodeslimitedtointrapulmonarylevelsaftercompleteexaminationofN1nodes.